Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Tóm tắt
Từ khóa
Tài liệu tham khảo
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE, Hughes CG, Vasilevskis EE, Shintani AK, Moons KG. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306–16.
Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, Douglas IS, Malhotra A, Owens RL, Feinstein DJ, Khan B. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506–16.
Veillette JJ, Van Epps P. Ertapenem-induced hallucinations and delirium in an elderly patient. Consult Pharm. 2016;31(4):207–14.
Apodaca K, Baker J, Bin-Bilal H, Raskin Y, Quinn DK. Ertapenem-induced delirium: a case report and literature review. Psychosomatics. 2015;56(5):561–6.
Lin H, Chew ST. Status epilepticus and delirium associated with ertapenem in a very elderly patient with chronic kidney disease and silent ischaemic cerebrovascular disease. Drug Saf Case Rep. 2015;2(1):19.
Africa BL, Carthen D, Arabelo H. A4 Delirious because of treatment: an adverse effect of imipenem. J Am Geriatr Soc. 2012;60:S18.
Fernández-Torre JL, Velasco M, Gutiérrez R, Fernández-Sampedro M. Encephalopathy secondary to imipenem therapy. Clin EEG Neurosci. 2004;35(2):100–3.
Serio RN. Acute delirium associated with combined diphenhydramine and linezolid use. Ann Pharmacother. 2004;38(1):62–5.
Ozsoylar G, Sayin A, Bolay H. Clarithromycin monotherapy-induced delirium. J Antimicrob Chemother. 2007;59(2):331.
Mermelstein HT. Clarithromycin-induced delirium in a general hospital. Psychosomatics. 1998;39(6):540–2.
Pollak PT, Sketris IS, MacKenzie SL, Hewlett TJ. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother. 1995;29(5):486–8.
Cone LA, Padilla L, Potts BE. Delirium in the elderly resulting from azithromycin therapy. Surg Neurol. 2003;59(6):509–11.
Pejčić AV. Delirium associated with the use of macrolide antibiotics: a review. Int J Psychiatry Clin Pract. 2020;1–14. https://doi.org/10.1080/13651501.2020.1828933
Tasleem H, Viswanathan R. Moxifloxacin-induced delirium with hallucinations. Psychosomatics. 2011;52(5):472–4.
Fennig S, Mauas L. Ofloxacin-induced delirium. J Clin Psychiatry. 1992;53(4):137–8.
Singh TD, O’Horo JC, Day CN, Mandrekar J, Rabinstein AA. Cefepime is associated with acute encephalopathy in critically ill patients: a retrospective case-control study. Neurocrit Care. 2020;33:695–700.
Grahl JJ, Stollings JL, Rakhit S, Person AK, Wang L, Thompson JL, et al. Antimicrobial exposure and the risk of delirium in critically ill patients. Crit Care. 2018;22(1):337.
Dakin LE. Probable trimethoprim/sulfamethoxazole-induced higher-level gait disorder and nocturnal delirium in an elderly man. Ann Pharmacother. 2009;43(1):129–33.
Velickovic-Radovanovic R, Catic-Dordevic A, Dinic K, Radivojevic J, Zikic O, Cvetkovic T, et al. Metronidazole- and levofloxacin-induced psychotic disorders in chronic kidney patient. Eur J Hosp Pharm. 2019;26(6):347–9.
Tong MK, Siu YP, Yung CY, Kwan TH. Piperacillin/tazobactam-induced acute delirium in a peritoneal dialysis patient. Nephrol Dial Transplant. 2004;19(5):1341.
Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). 2020. https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed 1 Oct 2020.
Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. 2020. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 1 Oct 2020.
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–6.
MedDRA MSSO. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 23.1. 2020. https://admin.new.meddra.org/sites/default/files/guidance/file/SMQ_intguide_23_1_English.pdf. Accessed 1 Oct 2020.
Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.
Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17(6):1–6.
Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008;42(12):1843–50.
Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21(1):276.
Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H. Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem. Int J Clin Pharm. 2013;35(5):683–7.
Chaïbi K, Chaussard M, Soussi S, Lafaurie M, Legrand M. Not all β-lactams are equal regarding neurotoxicity. Crit Care. 2016;20(1):1–2.
Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin. 1999;17(4):883–900.
BY the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94.
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8.